Recruiting
Phase 1

NTR-1011

Sponsor:

Neutrolis

Code:

NCT07237659

Conditions

SLE (Systemic Lupus)

RA - Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

NTR1011

Study Details

Brief summary:

The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It will also learn about the safety of NTR-1011 in healthy adult volunteers. The main questions it aims to answer are:

  • What is the highest dose of NTR-1011 that is safe and well tolerated, when given under the skin or into a vein?
  • How does the body process NTR-1011, and how does NTR-1011 affect the body?
  • Does the body develop an immune response to NTR-1011?
  • Are there early signs that NTR-1011 may benefit patients with SLE or RA when added to their current standard-of-care treatment?

In the first part of the study (Phase 1a, now complete), researchers compared single doses of NTR-1011 to a placebo (a look-alike substance that contains no drug) in 48 healthy volunteers to see how the body tolerates and processes the drug.

In the current part of the study (Phase 1b, actively recruiting), all participants receive NTR-1011 in addition to their usual SLE or RA treatment; there is no placebo group. Up to 24 participants with moderate-to-severe SLE or RA will:

  • Receive five weekly doses of NTR-1011 given directly into a vein (intravenous)
  • Continue their current standard-of-care treatment throughout the study
  • Be monitored for 4 weeks after their last dose
  • Be assigned to either the SLE group or the RA group (up to 12 patients each)

Conditions

SLE (Systemic Lupus)

RA - Rheumatoid Arthritis

Study ID

NCT07237659

Start date

Jul 15, 2026

Status verified date

Jul, 2026

Completion date

Aug 31, 2027

Anticipated

Primary completion date

Mar 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Phase 1a - Healthy Volunteers (Completed, No Longer Enrolling)

Key Inclusion Criteria

  • Healthy men and women, 18-55 years of age
  • Body mass index (BMI) between 17.0 and 30.0 kg/m²
  • Good general health, confirmed by medical history, physical exam, vital signs, ECG, and lab testing
  • Willing and able to use highly effective contraception during and after the study

Key Exclusion Criteria

  • Pregnant or breastfeeding
  • History of drug allergies or anaphylaxis to human, murine, or yeast proteins, monoclonal antibodies, or other allergens
  • Use of an investigational drug within 30 days (or 5 half-lives) before dosing
  • Positive test for hepatitis B, hepatitis C, or HIV
  • Clinically significant heart, lung, digestive, blood, autoimmune, psychiatric, or other medical condition
  • Clinically significant abnormal lab values (e.g., liver enzymes, blood counts) or ECG findings
  • Uncontrolled high blood pressure
  • Poor venous access

Phase 1b - Adult Patients with SLE and RA (Actively Recruiting)

General Inclusion Criteria (All Patients)

  • Men and women, 18-75 years of age
  • Able to understand and sign informed consent, and comply with study visits
  • Willing and able to use highly effective contraception during and after the study

Additional Inclusion Criteria - SLE Patients

  • Diagnosis of SLE for at least 6 months, meeting 2019 EULAR/ACR classification criteria
  • Active disease at screening
  • Positive lupus-related antibodies (e.g., anti-dsDNA, anti-Smith) and low complement (C3/C4)
  • On stable standard-of-care background therapy (e.g., antimalarials, low-dose corticosteroids, and at least one conventional DMARD)
  • Up to date on age-appropriate vaccinations Additional Inclusion Criteria - RA Patients
  • Diagnosis of RA for at least 3 months, meeting 2010 ACR/EULAR classification criteria
  • Moderate-to-severe active disease
  • Seropositive for rheumatoid factor and/or anti-CCP antibodies
  • On stable standard-of-care background therapy (e.g., low-dose corticosteroids and at least one conventional DMARD)

Key Exclusion Criteria (All Patients)

  • Pregnant or breastfeeding
  • Known allergy or reaction to NTR-1011, placebo components, or related products
  • Use of an investigational drug within 30 days (or 5 half-lives) before dosing, or concurrent enrollment in another clinical trial
  • History of cancer within the past year (with limited exceptions)
  • Significant kidney impairment, severe liver dysfunction, or severe lung disease
  • Uncontrolled high blood pressure or significant cardiovascular disease (e.g., recent heart attack or stroke, certain arrhythmias)
  • Active, recurrent, or high-risk infection, including active or latent tuberculosis without appropriate treatment, opportunistic infections, or chronic hepatitis B
  • Recent symptoms of COVID-19 without a documented negative test
  • Receipt of a live vaccine within 4 weeks before screening or planned within 4 weeks after last dose
  • Significant central nervous system disease or pain-amplification conditions (e.g., epilepsy, fibromyalgia) that could interfere with study assessments
  • Major surgery within 8 weeks before screening or planned within 6 months after baseline
  • History of bone marrow, stem cell, or solid organ transplant (except cornea)
  • Uncontrolled diabetes within the past 12 months (with some exceptions)
  • History of a blood clot within the past 12 months (with some exceptions)
  • Clinically significant abnormal lab values (e.g., liver enzymes, blood counts) at screening

Study Design

Enrollment

24 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: starting dose IV Patient

expected enzymatically and pharmacologically active IV dose in human SLE and RA patients

Interventions

NTR1011

NTR-1011 will be presented as a solution for intravenous (IV) administration.

Primary outcome measure

  • Safety and tolerability [ Time Frame: 30 days ]

Central Contacts and Locations

Central contacts

Andreas Reiff, MD, PhD

(626) 264-2734reiff@neutrolis.com

Ken Olivier, PhD

617-949-1575olivier@neutrolis.com

Locations

Carewell Arthritis Center

Recruiting

Apple Valley, California, United States, 92307

Contacts

Diraj Karmani, MD

909-581-8477

Attune Health Research Inc

Recruiting

Beverly Hills, California, United States, 90211

Contacts

Swamy Venuturupalli, MD

310-652-0010

Covina Arthritis Clinic

Recruiting

Covina, California, United States, 91722

Contacts

Samy Metyas, MD

626-966-1909info@MedvinResearch.com

Novamed

Recruiting

Monterey Park, California, United States, 91752

Contacts

Soha Dolatabadi, MD

213-266-8200

Southland Arthritis Clinic

Recruiting

Riverside, California, United States, 92508

Contacts

Amal Mehta, MD

951-924-6500

Southland Arthritis Clinic

Recruiting

Temecula, California, United States, 92592

Contacts

Amal Mehta, MD

714-244-2279

Foothill Arthritis Clinic

Recruiting

Tujunga, California, United States, 91042

Contacts

Dan La, MD

213-281-5146

More Information

Sponsor

Neutrolis

Last update posted

Jul 20, 2026

Last verified

Jul, 2026

Keywords

  • LIBERATE-I
  • Neutrolis
  • DNase1L3 fusion protein
  • DNase1L3 analogue

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Neutrolis on 2026-07-20.